Literature DB >> 18676764

Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor.

Cheryl L-L Chiang1, Jonathan A Ledermann, Egla Aitkens, Elizabeth Benjamin, David R Katz, Benjamin M Chain.   

Abstract

PURPOSE: Hypochlorous acid, a product of neutrophil myeloperoxidase, is a powerful enhancer of antigen processing and presentation. In this study, we examine whether ovarian epithelial cells (SK-OV-3) exposed to hypochlorous acid can stimulate T cells from patients with ovarian epithelial cancer that recognize common tumor antigens as well as autologous tumor. EXPERIMENTAL
DESIGN: T cells from human leukocyte antigen (HLA)-A2(+) and HLA-A2(-) patients or healthy controls were stimulated with autologous dendritic cells cocultured with the generic ovarian tumor line SK-OV-3, previously exposed to hypochlorous acid.
RESULTS: Hypochlorous acid-treated SK-OV-3 cells drove expansion of CD8(+) T cells from HLA-A2(+) individuals, which recognized the HLA-A2-restricted tumor antigen epitopes of HER-2/neu (E75 and GP2) and MUC1 (M1.1 and M1.2). Up to 4.1% of the T cells were positive for the HER-2/neu KIFGSLAFL epitope using pentamer staining. Dendritic cells loaded with oxidized SK-OV-3 cells and further matured with CD40 agonistic antibody or monophosphoryl lipid A additionally induced CD4(+) class II-restricted responses. Critically, T cells stimulated with mature oxidized SK-OV-3 (but not a control oxidized melanoma cell line) directly recognized autologous tumor cells isolated from patient ascites.
CONCLUSIONS: Immunization with mature dendritic cells loaded with a generic oxidized tumor cell line stimulates a polyclonal antitumor response that recognizes autologous tumor. These findings suggest a new immunotherapeutic strategy to extend remission in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676764     DOI: 10.1158/1078-0432.CCR-07-4899

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

Review 1.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

2.  A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Authors:  Cheryl Lai-Lai Chiang; Lana E Kandalaft; Janos Tanyi; Andrea R Hagemann; Gregory T Motz; Nikolaos Svoronos; Kathleen Montone; Gina M Mantia-Smaldone; Lori Smith; Harvey L Nisenbaum; Bruce L Levine; Michael Kalos; Brian J Czerniecki; Drew A Torigian; Daniel J Powell; Rosemarie Mick; George Coukos
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

Review 3.  Mechanisms regulating immune surveillance of cellular stress in cancer.

Authors:  Ruth Seelige; Stephen Searles; Jack D Bui
Journal:  Cell Mol Life Sci       Date:  2017-07-25       Impact factor: 9.261

Review 4.  Danger signalling during cancer cell death: origins, plasticity and regulation.

Authors:  A D Garg; S Martin; J Golab; P Agostinis
Journal:  Cell Death Differ       Date:  2013-05-17       Impact factor: 15.828

Review 5.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

6.  Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease.

Authors:  Nicola Hardwick; Jonathan A Ledermann; Egla Aitkens; Benny Chain
Journal:  Cancer Immunol Immunother       Date:  2012-04-05       Impact factor: 6.968

7.  Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.

Authors:  Cheryl L-L Chiang; Dawn A Maier; Lana E Kandalaft; Andrea L Brennan; Evripidis Lanitis; Qunrui Ye; Bruce L Levine; Brian J Czerniecki; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2011-11-14       Impact factor: 5.531

8.  Trial watch: Dendritic cell-based interventions for cancer therapy.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

9.  A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Cheryl L Chiang; Janos Tanyi; Greg Motz; Klara Balint; Rosemarie Mick; George Coukos
Journal:  J Transl Med       Date:  2013-06-18       Impact factor: 5.531

10.  Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS.

Authors:  Iart Luca Shytaj; Barbara Chirullo; Wendeline Wagner; Maria G Ferrari; Rossella Sgarbanti; Alessandro Della Corte; Celia LaBranche; Lucia Lopalco; Anna Teresa Palamara; David Montefiori; Mark G Lewis; Enrico Garaci; Andrea Savarino
Journal:  Retrovirology       Date:  2013-07-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.